For most of his career, he has been working in the field of clinical practice, teaching and the scientific research of oncology. He has published more than 300 articles in peer reviewed domestic and international journals. In addition to the academic career, he is an expert oncologist whose current research focus is experimental therapeutics and early clinical development of novel targeting agents and immune-oncology drugs. Professor Kang is actively involved in clinical trials and has been an investigator in over 130 clinical trials evaluating novel agents in both lung cancer, esophageal cancer, head and neck cancer, and malignant melanoma. He is also interested in cancer research and discovered a novel driver oncogene, KIF5B-RET in a young Korean non-small cell lung cancer patient in 2012. He has been working as the president in Korean Cancer Study Group (KCSG) since 2016 as well as a member of domestic and international scientific societies including ASCO, AACR, and IASLC. Professor Kang has contributed to the review and evaluation of clinical study of novel anti-cancer drugs and the bioequivalent test of generic drugs as an Executive Consultant of MFDS since 2002. He is carrying out the R&D Projects funded from KNCC (Korean National Cancer Center, Cancer Conquer Project), NRF (National Research Foundation), and HIRA(Health Insurance Review & Assessment Service) .